Novel predictors of immune checkpoint inhibitor response and prognosis in advanced non‐small‐cell lung cancer with bone metastasis
Cancer Medicine · 2023
DOI: 10.1002/cam4.5952 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2023. Verfasst von Yohei Asano und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedic Surgery, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Bone Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Backgrounds Immune checkpoint inhibitors (ICIs) can significantly prolong the survival of patients with advanced non‐small‐cell lung cancer (NSCLC); however, few studies on the therapeutic effects of ICIs on bone metastases were performed.
Methods
This retrospective study aimed to investigate the therapeutic effects of ICIs and determine predictors of favorable ICI response and prognosis in 55 advanced NSCLC patients with bone metastases who initiated ICI treatment between 2016 and 2019, with a mean follow‐up period of 23.2 months. Patients were classified into responders (complete or partial response) and non‐responders (stable or progressive disease) according to the MD Anderson Cancer Center (MDA) criteria, and the predictors of therapeutic response were identified using multivariate logistic regression analysis. Furthermore, overall survival from the time of ICI administration to the final follow‐up or death was evaluated, and prognostic predictors were identified using Cox proportional hazards regression analysis.
Results
ICI response rate was 30.9% (complete in three cases, partial in 14). Median survival time was 9.3 months, with 1‐year and 2‐year survival rates of 40.6% and 19.3%, respectively. Responders survived significantly longer than non‐responders ( p = 0.03). Based on the receiver operating characteristic curve, the predictive cutoff value of the pretreatment neutrophil‐to‐lymphocyte ratio (NLR) was 2.1. Multivariate analysis identified female sex ( p = 0.03), use of ICIs as first‐line therapy ( p < 0.01), and NLR
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopaedic Surgery, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan.
- Department of Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Japan.
- Department of Respiratory Medicine, Ishikawa Prefectural Central Hospital, Kanazawa, Japan.
- Department of Radiology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan.
- Department of Thoracic Surgery, Kanazawa University, Kanazawa, Japan.
ORCID-Profile: Yohei Asano, Norio Yamamoto, Satoshi Kato, Shinji Miwa, Takashi Higuchi
Zitieren
APA
Asano, Y., Yamamoto, N., Demura, S., Hayashi, K., Takeuchi, A., Kato, S., Miwa, S., Igarashi, K., Higuchi, T., Taniguchi, Y., Morinaga, S., Sone, T., Okuda, M., Matsumoto, I., Yano, S., & Tsuchiya, H. (2023). Novel predictors of immune checkpoint inhibitor response and prognosis in advanced non‐small‐cell lung cancer with bone metastasis. Cancer Medicine. https://doi.org/10.1002/cam4.5952
Vancouver
Asano Y, Yamamoto N, Demura S, Hayashi K, Takeuchi A, Kato S, et al. Novel predictors of immune checkpoint inhibitor response and prognosis in advanced non‐small‐cell lung cancer with bone metastasis. Cancer Medicine. 2023. doi:10.1002/cam4.5952
BibTeX
@article{Asano2023,
author = {Asano, Yohei and Yamamoto, Norio and Demura, Satoru and Hayashi, Katsuhiro and Takeuchi, Akihiko and Kato, Satoshi and Miwa, Shinji and Igarashi, Kentaro and Higuchi, Takashi and Taniguchi, Yuta and Morinaga, Sei and Sone, Takashi and Okuda, Miho and Matsumoto, Isao and Yano, Seiji and Tsuchiya, Hiroyuki},
title = {Novel predictors of immune checkpoint inhibitor response and prognosis in advanced non‐small‐cell lung cancer with bone metastasis},
journal = {Cancer Medicine},
year = {2023},
doi = {10.1002/cam4.5952}
}
EUVIMED